tbuckley/cabot-search huggingface dataset:
Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
Authors: Avivit Peer, Maya Ish-Shalom, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Roberto Pili, Natalie Maimon, Maya Gottfried, Henry Hayat, Svetlana Kovel, Avishay Sella, Avivit Neumann, Ben Boursi, Raanan Berger, Michael Anthony Carducci, Daniel Keizman
Journal: Journal of Clinical Oncology (2012)

4619 Background: Bis are used to prevent skeletal events of bone mets, and may exhibit anti tumor effects. We aimed to evaluate whether Bis can bring a RR, PFS, and OS benefit to pts with bone mets from RCC that are treated with Su. Methods: We performed an international multicenter retrospective study of pts with bone mets from RCC who were treated with Su. Pts were divided into Bis users (group 1) and nonusers (group 2). The effect of Bis on RR, PFS and OS, was tested with adjustment for known prognostic factors using a chisquare test from contingency table and partial likelihood test from Cox regression model. Results: Between 2004-2011, 244 pts with metastatic RCC were treated with Su. 92 pts had bone mets, 41 group 1 and 51 group 2. The groups were balanced regarding the following known prognostic factors: past nephrectomy, clear cell vs non clear cell histology, initial diagnosis to sunitinib treatment (tx) time, presence of ≥ 2 mets sites, presence of lung/liver mets, ECOG performance status, anemia, calcium level &gt; 10 mg/dL, elevated alkaline phosphatase (AP), pre-tx neutrophil to lymphocyte ratio (NLR) &gt;3, sunitinib induced HTN, and the use of angiotensin system inhibitors. They were also balanced with regard to past cytokines/targeted tx, and mean sunitinib dose/cycle. Objective response was partial response/stable disease 85% (n=35) vs 71% (n=36), and progressive disease 15% (n=6) vs 29% (n=15) (OR 3.287, p=0.07) in group 1 vs 2 respectively. Median PFS was 15 vs 5 months (HR 0.433, p=0.035), and median OS not reached with a median folloup time of 43 mos vs 12 months (HR 0.398, p=0.003), in favor of group 1. In multivariate analysis of the entire pt cohort (n=92), factors associated with PFS were Bis use (HR 0.433, p=0.035), pre-tx NLR ≤3 (HR 0.405, p=0.016), and elevated AP (HR=3.63, p=0.012). Factors associated with OS were Bis use (HR 0.32, p=0.003), elevated AP (HR 3.18, p=0.002), and Su induced HTN (HR 0.193, p&lt; 0.001). Conclusions: Bis may improve the outcome of Su tx in RCC with bone mets. This should be investigated prospectively, and if validated applied in clinical practice and clinical trials.
Diaphragmatic Breathing Exercises
Authors: Marvin A. Sackner
Journal: JAMA (1975)

DIAPHRAGMATIC breathing exercises have long been advocated in the therapy of patients with chronic obstructive pulmonary disease (COPD). The control of diaphragmatic excursions is accomplished by (1) consciously contracting the muscles of the anterior abdominal wall to obtain preferential descent of the diaphragm during inspiration, (2) assuming the head-down, supine, or leaning-forward posture to facilitate a diaphragmatic breathing pattern, and (3) placing weights or strapping belts on the abdomen to force the diaphragm craniad.<sup>1-3</sup> Often, dyspnea is relieved by these maneuvers, but it is uncertain what are the mechanisms responsible for the improvement. The following hypotheses have been suggested: (1) reduction of minute ventilation with maintenance of alveolar ventilation, (2) slowing of inspiratory flow rates, (3) improvement of ventilation-perfusion relationships at the bases of the lungs, (4) diminution of the work of breathing, and (5) promotion of a feeling of well-being. <h3>Reduction of Dead-Space Ventilation</h3> The hypothesis that reduced
Anti–Sia-lb (Anti-Gd) Cold Agglutinins Bind the Domain NeuNAcα2-3Gal in Sialyl Lewisx, Sialyl Lewisa, and Related Carbohydrates on Nucleated Cells and in Soluble Cancer-Associated Mucins
Authors: Teresa Gallart, Dieter Roelcke, Maite Blay, Arturo Pereira, Antonio Martı́nez, Oriol Massó, Odette Viñas, Mariona Cid, Jordi Esparza, Rafael Molina, Juanjo Barceló
Journal: Blood (1997)
In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee
Journal: Journal of Thoracic Oncology (2016)

The authors aimed to develop a new prediction model using the classification and regression tree (CART) analysis assessing the interaction of 29 variables with 18month survival in malignant pleural mesothelioma (MPM).From the 482 cases in the derivation cohort with median survival of 12.6 months and median age of 69 years, 4 risk groups were identified by the model with significant survival differences (p < 0.0001).Weight loss was the strongest predictive variable.The best survival at 18 months (86.7% alive: 'risk group 1', median survival 34.0 months) was achieved in the group with no weight loss, haemoglobin >153 g/L and serum albumin >43 g/L while the worst (0% alive: 'risk group 4d', median survival 7.5 months) was achieved in those with weight loss, performance score 0-1 and sarcomatoid histology.The model was validated on an external cohort of 174 cases (C-statistic 0.68).To conclude, the authors have developed and validated a simple and clinically relevant model to stratify MPM patients at high and lower risk of death based on routinely available variables from a large, unselected population at diagnosis.(p.573)
DILATATION AND HYPERTROPHY OF THE HEART
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Growth Retardation: Use of Sulfation Factor as a Bioassay for Growth Hormone
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
Authors: Milagritos D Tapia, Samba O Sow, Khardiata D Mbaye, Aliou Thiongane, Birahim P Ndiaye, Cheikh T Ndour, Souleymane Mboup, Babajide Keshinro, Thompson N Kinge, Guy Vernet, Jean Joel Bigna, Stephen Oguche, Kwadwo A Koram, Kwaku P Asante, Patrice Gobert, Wayne R Hogrefe, Iris De Ryck, Muriel Debois, Patricia Bourguignon, Erik Jongert, William R Ballou, Marguerite Koutsoukos, François Roman, Senate Amusu, Leo Ayuk, Catherine Bilong, Owusu Boahen, Makhtar Camara, Fadima Cheick Haidara, Daouda Coly, Siry Dièye, David Dosoo, Melanie Ekedi, Irma Eneida Almeida Dos Santos, Seyram Kaali, Afoke Kokogho, Myron Levine, Nick Opoku, Seth Owusu-Agyei, Simon Pitmang, Fatima Sall, Moussa Seydi, Marcelo Sztein, Mathurin Tejiokem, Awa Traore, Marie-Astrid Vernet, Abena Kunadu Yawson
Journal: The Lancet Infectious Diseases (2020)
&lt;emph type="bold"&gt;Florence Nightingale&lt;/emph&gt;
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEMBERSHIP OF EDUCATIONAL COMMITTEES (AS OF OCT 1, 1982)
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NECROLOGY.
Authors: William Lee
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CERTAIN PUBLIC HEALTH PROBLEMS IN BRUCELLIASIS
Journal: JAMA (1930)

Much is being written today on the public health aspects of the undulant fever problem. A recently published bulletin of the California Department of Public Health<sup>12</sup>on this subject, prepared by the University of California committee for the study of this disease, is timely. It covers fully the history, the principal clinical characteristics, the epidemiology and the control measures for undulant fever. The epidemiologic feature carries the following significant statements as to infection from raw milk: "Raw milk from goats or cows should not be directly blamed unless laboratory data are obtained as the<i>shedding of organisms</i>in the milk or the extent of the infection in the herd determined by agglutination tests or by history of recent abortions in the herd or the recent use of live organism abortus vaccines, or by positive results from direct inoculation of guinea-pigs of centrifugalized specimens of pooled milk samples. Any assumption
Whole-Body Protein Turnover in Humans--Past, Present, and Future
Authors: J. Waterlow
Journal: Annual Review of Nutrition (1995)

Protein turnover is a fundamental biological process in all living organisms. The study of protein turnover in human subjects, and in the body as a whole, is of relatively recent origin. In this review, I summarize briefly how this field of work has expanded over the past 25 years, with emphasis on conceptual problems and controversies, particularly those related to methods of measurement. We cannot be certain that our estimates are accurate because no method of verification exists, but progress will be made through successive approximations. Some of the applications are described in different physiological and pathological states such as growth and trauma, and possible directions for fruitful future research are indicated.
Phototherapy.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bleeding Manifestations and Management of Children with Persistent and Chronic Immune Thrombocytopenia (ITP): Data From the Intercontinental Cooperative ITP Study Group.
Authors: Cindy Neunert, George R. Buchanan, Paul A. Imbach, Paula HB Bolton-Maggs, Carolyn M. Bennett, Ellis J Neufeld, Sara K. Vesely, Leah Adix, Victor S. Blanchette, Thomas Kuehne
Journal: Blood (2009)
Medicinal Herbs in the United States: Research Needs
Authors: Hazel B. Matthews, George W. Lucier, Kenneth D. Fisher
Journal: Environmental Health Perspectives (1999)

Virtually all cultures have, throughout history, used a variety of plants or materials derived from plants for the prevention and treatment of disease. Evidence of the beneficial therapeutic effects of these medicinal herbs is seen in their continued use. Additionally, the development of modern chemistry permitted the isolation of chemicals from medicinal herbs that have served as drugs or starting materials for the synthesis of many important drugs used today. Many more modern drugs have been synthesized as a result of knowledge gained from studies of mechanisms of actions of chemicals first isolated from medicinal herbs. Thus, medicinal herbs have played a major role in the development of modern medicine and continue to be widely used in their original form. Whereas it is generally agreed that most medicinal herbs are safe under the conditions used, some are toxic and should be avoided even though they are readily available, and others have significant adverse side effects when misused. Also, little has been done to investigate potential adverse effects that may be associated with extended or high-dose use of medicinal herbs. Thus, concern has been expressed that the lack of quality control used in the preparation of medicinal herbs, plus their unregulated sale and uninformed use, pose potential adverse health effects for consumers. There is also concern regarding potential herb/herb or herb/drug interactions and possible untoward health effects of medicinal herbs in sensitive subpopulations such as the young and the elderly and certain genetically predisposed individuals. In this paper, we discuss these concerns at some length and make recommendations for additional research and education discussed in the recent International Workshop to Evaluate Research Needs on the Use and Safety of Medicinal Herbs.
Praktische Diätetik mit über 500 Kochrezepten für diätetische Behandlung für Ärzte und Patienten.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.
Authors: David Stephen Shulman, Cecilia Carlowicz, Clay Gustafson, Kieuhoa Tran Vo, Elizabeth Fox, Jodi Ann Muscal, Jeffrey G. Supko, Andrew E. Place, Susan N. Chi, Suzanne Shusterman, Gina Hanna, Jane O'Brien, Suzanne Ezrre, Pei-Chi Kao, Wendy B. London, Steven G. DuBois
Journal: Journal of Clinical Oncology (2018)

10542 Background: CUDC-907 is a first-in-class small molecule inhibitor of histone deacetylases and phosphatidylinositol-3-kinases. Data from pediatric preclinical models, and adult clinical studies suggest that CUDC-907 can downregulate Myc/Mycn, providing a potential therapeutic strategy for Myc/Mycn-driven pediatric tumors. Methods: Using a 3+3 dose escalation design, CUDC-907 was administered at 3 dose levels to patients 1-21 years of age with relapsed/refractory solid tumors, brain tumors and lymphomas (NCT02909777). Primary objectives were to determine the pediatric recommended phase II dose (RP2D), describe toxicities, and describe PK parameters. Other endpoints included antitumor activity and pharmacodynamic effects. Patients received CUDC-907 orally on a 5 days on / 2 days off ("5/2") schedule in 28-day cycles, with a pediatric mini-tab formulation for children who could not swallow pills. Results: As of 11/16/2017, 15 patients enrolled, with a median age of 15 (4.6-20.9) years. Diagnoses included: osteosarcoma (n = 4); alveolar rhabdomyosarcoma (n = 3); DIPG (n = 2); ependymoma (n = 2); Ewing sarcoma (n = 2); CNS germ cell tumor (n = 1); and alveolar soft part sarcoma (n = 1). Patients received a median of 2 (1-7+) cycles. No DLTs were observed in 3 evaluable patients each at dose levels 1 and 2. A single first cycle DLT (grade 3 metabolic acidosis) was observed in 1 of 6 evaluable patients at dose level 3 (45 mg/m2; 128% of the adult RP2D). The most common treatment-related AEs were: thrombocytopenia (87%), nausea (80%), lymphopenia (80%), diarrhea (73%), leukopenia (73%), anemia (67%), tachycardia (67%), vomiting (67%), fatigue (67%), and anorexia (67%). The mean Tmax was 2.5 hrs and T1/2 was 1.4 hrs. No objective responses were seen. One patient with Ewing sarcoma and one patient with ependymoma had stable disease for 6 and 7+ cycles, respectively. Pharmacodynamic studies are pending. Conclusions: CUDC-907 was well tolerated with a pediatric RP2D of 45 mg/m2 administered orally on a 5/2 schedule. An expansion stage will evaluate this dose in groups of interest: mature B-cell lymphoma; MYCN amplified neuroblastoma; and solid tumors with MYC/MYCN amplification/high-copy gain. Clinical trial information: NCT02909777.
Incorrect Column Headings in 2 Tables
Journal: JAMA Network Open (2019)

In the Original Investigation titled "Patterns in Outpatient Benzodiazepine Prescribing in the United States," 1 published January 25, 2019, the headings for 2 columns were incorrect in Tables 1 and2.In both tables, the sample sizes should not have appeared in the headings for the first 2 data columns, and the word "unweighted" should not have appeared in the spanning heading above those columns because the data are weighted.